OREANDA-NEWS. PSI CRO, a full-service contract research organization, announced today that the company has been selected by Synta Pharmaceuticals to conduct their GALAXY-2 trial, a Randomized Phase III Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Cancer. PSI is currently initiating this 500-patient study across 15+ countries.

PSI has been conducting clinical trials in oncology since 1994. Lung cancer represents one of the central oncological indications in the PSI portfolio. PSI’s commitment to thorough feasibility and “go-the-extra-mile“project management, has secured PSI’s reputation for high quality and on-time delivery in the area of lung cancer.

Synta Pharmaceuticals, located in Lexington, MA, is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All drug candidates were invented internally by Synta scientists using their compound library and discovery capabilities.

PSI is a privately-held, full-service contract research organization (CRO), operating globally with 1,200 employees worldwide. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300.